Live-attenuated bacteria as a cancer vaccine vector.

作者: Bertrand Toussaint , Xavier Chauchet , Yan Wang , Benoit Polack , Audrey Le Gouëllec

DOI: 10.1586/14760584.2013.836914

关键词:

摘要: In the emerging field of active and specific cancer immunotherapy, strategies using live-attenuated bacterial vectors have matured in terms academic industrial development. Different species can be genetically engineered to deliver antigen APCs with strong adjuvant effects due their microbial origin. Proteic or DNA-encoding delivery routes natural tropisms might differ among species, permitting different applications. After many efforts resolve safety efficacy issues, some firms recently engaged clinical trials live Listeria Salmonella spp. We describe here main technological advances that allowed bacteria become one most promising immunotherapy.

参考文章(107)
F. S. Southwick, D. L. Purich, Listeria and Shigella actin-based motility in host cells. Transactions of the American Clinical and Climatological Association. ,vol. 109, pp. 160- ,(1998)
Heather A. Carleton, Pathogenic bacteria as vaccine vectors: teaching old bugs new tricks. Yale Journal of Biology and Medicine. ,vol. 83, pp. 217- 222 ,(2010)
Ivan King, Martina Itterson, David Bermudes, Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy. Methods of Molecular Biology. ,vol. 542, pp. 649- 659 ,(2009) , 10.1007/978-1-59745-561-9_33
D A Portnoy, Y Paterson, S A Brassell, R Schafer, Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine. Journal of Immunology. ,vol. 149, pp. 53- 59 ,(1992)